The phase 3 POIESIS trial is set to investigate navtemadlin as an add-on therapy to Jakafi in patients with JAK inhibitor-naive myelofibrosis.

including CTGF/CCN2 and WISP1/CCN4, on multiple cell types contributing to the fibrotic pathology. This approach is an evolution from blocking individual CCN proteins and their upstream activator, TGF ...

What is the significance of the PDE4B pathway in the pathogenesis of IPF and PPF? What has the data demonstrated with nerandomilast so far, and what future data is needed for this therapy? How do you ...

Programs address the need for disease-modifying therapies targeting root causes of fibrosis Funding will support ... other CCN family members, including CTGF/CCN2 and WISP1/CCN4, on multiple ...

Programs address the need for disease-modifying therapies targeting root causes of fibrosis Funding will support ... other CCN family members, including CTGF/CCN2 and WISP1/CCN4, on multiple ...

Introduction: Renal fibrosis ... pathway. Experimental validation further confirmed that YQQRG suppressed the PI3K/AKT pathway in the renal tissues of UUO mice; the addition of the PI3K/AKT agonist ...

rug.nl Rationale We have previously shown increased expression of the Frizzled-8 receptor of the Wingless/integrase-1 (WNT) signalling pathway in COPD. Here, we investigated if the Frizzled-8 receptor ...

The canonical Smad pathway was specifically targeted by small interfering ... The mouse model of bleomycin-induced dermal fibrosis was used to assess the role of JunD in experimental fibrosis.

Department of Cardiology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, Guangdong Province, P. R. China Department of Cardiology, The Eighth Affiliated Hospital of Sun Yat ...

They also found genes involved in the mTOR signaling pathway, which is central in lung fibrosis, and in mucin fucosylation, which may influence airway self-clearing mechanisms. Additionally, previous ...